Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Waxman/Hatch extensions may be added to 20-year GATT term for most patents -- federal appeals court.

Executive Summary

WAXMAN/HATCH EXTENSIONS MAY BE ADDED TO 20-YEAR GATT PATENT TERM if the original 17-year term of the patent was in force at the time the Uruguay Rounds Agreement Act took effect June 8, 1995, under a ruling by the D.C. federal appeals court. Chief Judge Glenn Archer, Senior Circuit Judge Helen Nies and Circuit Judge Paul Michel decided the consolidated cases of Merck, Schering-Plough, Bracco, Roche and Organon v. FDA, the Patent & Trademark Office and the Generic Pharmaceutical Industry Association April 4. The court issued a split ruling: patents that were in force when the URAA took effect by virtue of Waxman/Hatch extensions will not be able to add the Waxman/Hatch time to a 20-year term.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS028012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel